Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0146)
| Name |
Fingolimod
|
||||
|---|---|---|---|---|---|
| Synonyms |
Fingolimod; 162359-55-9; 2-Amino-2-(4-octylphenethyl)propane-1,3-diol; 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; Fty-720; Fingolimod [INN]; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol; 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-; Gilenya (TN); 3QN8BYN5QF; 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-; CHEMBL314854; CHEBI:63115; Fingolimod (INN); 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol; FTY-720A; UNII-3QN8BYN5QF; 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol; fingolimodum; Fingolimod- Bio-X; FINGOLIMOD [MI]; FINGOLIMOD [VANDF]; FINGOLIMOD [MART.]; SCHEMBL7445; FINGOLIMOD [WHO-DD]; GTPL2407; FINGOLIMOD [ORANGE BOOK]; DTXSID40167363; KKGQTZUTZRNORY-UHFFFAOYSA-N; HMS3743O13; AMY22173; BCP05969; BDBM50158336; NSC755643; s5950; STL445699; AKOS015999594; DB05286; DB08868; NSC-755643; NCGC00188399-01; NCGC00188399-03; NCGC00188399-04; NCGC00188399-06; NCGC00188399-16; AC-25899; AS-68987; BF164460; HY-11063; FT-0660847; 2-(4-octylphenethyl)-2-aminopropane-1,3-diol; D10001; D70458; 2-amino-2-(4-octylphenyl)ethylpropane-1,3-diol; EN300-18802383; Q425137; 2-amino-2-hydroxymethyl-4-(4-(octyl)phenyl)butanol; BRD-K88025533-003-01-7; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C19H33NO2
|
||||
| IUPAC Name |
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
|
||||
| Canonical SMILES |
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
|
||||
| InChI |
InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
|
||||
| InChIKey |
KKGQTZUTZRNORY-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Multiple myeloma | ICD-11: 2A83 | ||
| Responsed Regulator | 5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) | Driver | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| AMPK signaling pathway | hsa04152 | |||
| Autophagy | hsa04140 | |||
| Cell Process | Cell ferroptosis | |||
| Cell autophagy | ||||
| In Vitro Model | U266B1 cells | Plasma cell myeloma | Homo sapiens | CVCL_0566 |
| RPMI-8226 cells | Plasma cell myeloma | Homo sapiens | CVCL_0014 | |
| Response regulation | Multiple myeloma (MM) is the second hematological plasma cell malignany and sensitive to fingolimod (FTY720), a novel immunosuppressant. Fingolimod (FTY720) can activate PP2A subunit C and dephosphorylate AMPKa, and then inhibit the expression of SLC7A11 and GPX4. In conclusion, FTY720 induces ferroptosis and autophagy through the PP2A/AMPK pathway. | |||